Featured on Reuters: Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies

“Eli Lilly Co and privately-held AbCellera Biologics Inc on Thursday announced they would co-develop antibody products for the treatment of COVID-19, a flu-like disease caused by the fast-spreading coronavirus.”

Read full coverage on Reuters.

PARTNERSHIP

Together we can make game-changing discoveries.